Enzon Pharma folds under pressure from shareholder activists
| August 11th, 2008 | ||
| Today, Enzon Pharmaceuticals (ENZN) announced that it would give into shareholder activists' demands and try to sell all or parts of its commercial business, which include four marketed drugs, royalties and a manufacturing plant in Indiana. The company is also attempting to spin off its biotech research arm as its own company called Evivrus Inc, although the company will remain a wholly owned subsidiary of Enzon. Enzon has been the target of shareholder activists Carl Icahn (7% stake in ENZN) and DellaCamera Capital Management (6.4% stake in ENZN), Both of these hedge fund firms have critical of ENZN's executive compensation and both have been pushing for a sale of its commercial businesses. | ||
For Detailed Investor Profiles on these Investors, click below: |
DellaCamera Capital Management |
Icahn Associates (Carl Icahn) |
Related People: Alexander J. Denner;
Related Entities: DellaCamera Capital Advisors;
Related Article Tags: Shareholder Activists, Corporate Raiders and Proxy Battles; Hedge Fund Launches and Hedge Fund Closings
Add a Comment |
More Recent Headlines
James Pallotta to spins off Tudor funds into Raptor Global |
Fortress gives $300 million share grant to Adam Levinson |
Gabelli Wants Break Up of Cablevision |
Steel Partners wants to put Point Blank in Range |
Massachusetts State Pension Fund drops Bill Miller |
Nationwide Mutual Insurance buys Nationwide Financial Services |
Dow Kim cancels launch of Diamond Lake |
Bristol-Myers Squibb Co. makes unsolicited bid for ImClone |
Hedge funds adopting “operational activism” approach |
T. Boone Pickens sells off his Yahoo shares at a loss |
